Hormonal
Inhibiting adipogenesis (the differentiation of preadipocytes into mature adipocytes) via modulation of transcription factors (C/EBP, PPARγ) and signaling pathways (Wnt, AMPK) is a viable therapeutic strategy for preventing or treating obesity.
This paper does not provide a direct lifestyle protocol but identifies the biological target: stopping the creation of new fat cells. For a layperson, this implies that interventions aiming to reduce obesity should focus on mechanisms that inhibit fat cell differentiation, such as those found in certain natural products or drugs targeting PPARγ or AMPK pathways, rather than just calorie restriction alone.
Therefore, the regulation of size and number of adipocytes might be a possible therapeutic approach for obesity, and it is important to understand the molecular mechanisms of adipose tissue formation and alterations in obesity. Identifying potential adipogenic molecular targets susceptible to modulation by external factors can utilize adipogenesis regulation to control or reverse obesity.
Why this rating
The paper is a review of in vitro (3T3-L1) and animal models; no human clinical trial data is presented.
Source
Adipogenesis as a Potential Anti-Obesity Target: A Review of Pharmacological Treatment and Natural Products
Jelena Jakab et al. · Diabetes Metabolic Syndrome and Obesity · 2021
DOI 10.2147/dmso.s281186
More from this paper
- Obesity is strongly associated with increased oxidative stress, chronic low-grade inflammation, and an increased risk of severe outcomes in infectious diseases like COVID-19.Good
- Natural products and conventional medications (Statins, Fibrates, Niacin) can inhibit or modulate adipogenesis through specific molecular pathways, offering potential anti-obesity effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →